ENGLEWOOD, Colo. / Jan 17, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA), is excited to announce the limited market release of its Bun-Yo-Matic™ Lapidus Clamp System and completion of the first surgical cases in Orange County, California and Seattle, Washington. The Bun-Yo-Matic™ is the only bunion solution on the market designed to intraoperatively simulate weight-bearing and allow for compression prior to hardware application. This unique approach provides surgeons a more reproducible and efficient means to restore three-dimensional alignment of the foot while accommodating each surgeon’s preferred fixation methodology in a Lapidus procedure.

The Bun-Yo-Matic™ Clamp remains fixed to the anatomy throughout the entire procedure, ensuring surgeon-guided correction and anatomic alignment are maintained through application of fixation. The System is also equipped with cutting guides designed to minimize bone removal from the base of Tarsometatarsal (“TMT”) joint when preparing for fusion.

The Bun-Yo-Matic™ Clamp and accompanying cut guide system are highly complementary to Paragon 28’s broad line of bunion and forefoot solutions. The Clamp is a reusable surgical instrument which will be used in conjunction with several of Paragon 28’s existing implants and implant systems designed to treat bunions, including:

• Gorilla^® Precision™ Lapidus Plate
• Phantom^® Small Bone Intramedullary Nail
• Phantom^® MIS Lapidus System allowing medial access
• MIS Burr Guide used in preparing the 1^st TMT joint

Paragon 28’s CEO, Albert DaCosta, commented, “The first clinical cases with the Bun-Yo-Matic™ Clamp System went great, and we expect this product to drive significant growth for Paragon 28. We believe this clamp is a game changer in the bunion market and will result in more reproducibility, streamlined procedural work flow, improved accuracy, and ultimately improved patient outcomes in technically demanding Lapidus arthrodesis cases. With the capability to hold correction across all three planes throughout the entire procedure, the system is unique and brings great value to our surgeons and patients.”

The Bun-Yo-matic™ Lapidus Clamp System bolsters Paragon 28’s bunion and forefoot solutions offering which includes the Gorilla^® Precision™ Lapidus Plate, Phantom^® Small Bone Intramedullary Nail, Phantom^® MIS System, Gorilla^® Precision MTP Plate, Phantom^® Metatarsal Shortening System, TenoTac™, Paratrooper™, and HammerTube™. With this comprehensive portfolio, Paragon 28^® provides its customers with a single source to address their bunion and forefoot needs.

About Paragon 28, Inc.

Based in Englewood, CO., Paragon 28 is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28^® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.

Forward Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Paragon 28’s potential to shape a better future for foot and ankle patients. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware. Forward‐looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward‐looking statements are based on Paragon 28’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward‐looking statements as a result of these risks and uncertainties. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Paragon 28’s business in general, see Paragon 28’s current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and its Quarterly Reports on Form 10-Q, as updated periodically with its other filings with the SEC. These forward-looking statements are made as of the date of this press release, and Paragon 28 assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Disclaimer

Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations.